# ReVenG (NCT04895436)

> Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04895436
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: AbbVie
- Conditions: Chronic Lymphocytic Leukemia (CLL)
- Interventions: Venetoclax; Obinutuzumab
- Enrollment: 75
- Primary outcome: Overall response (OR) in Cohort 1 after end of combination treatment

## Commentary we found

- YouTube: 12
- Podcasts: 9
- X threads: 2
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=reveng-nct04895436

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04895436", "email": "<work email>"}; the inbox owner confirms by the emailed link.